If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- ...
Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Cancer cells survive therapy by dynamically rewiring their metabolism in response to nutrient availability, ...
Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback